Related Experiment Video

Updated: May 10, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Short hairpin RNA modulates transforming growth factor beta signaling in life-threatening liver failure in mice

Yoshiaki Mizuguchi1, Shigeki Yokomuro, Takuya Mishima

  • 1Department of Surgery for Organ Function and Biological Regulation, Nippon Medical School, Tokyo, Japan.

Gastroenterology
|November 16, 2005
PubMed
Abstract

Insights

Short hairpin RNA targeting transforming growth factor beta receptor II (TGF-betaRII) silences the gene, protecting liver cells from injury. This RNA interference approach shows promise for treating liver failure and analyzing TGF-beta signaling pathways.

Area of Science:

  • Molecular Biology
  • Hepatology
  • Gene Therapy

Background:

  • Transforming growth factor beta (TGF-beta) receptor II (TGF-betaRII) is crucial for TGF-beta signaling and implicated in human diseases.
  • TGF-beta plays a key role in liver function, including hepatocyte apoptosis, growth inhibition, and fibrogenesis.
  • RNA interference (RNAi) offers potential for in vivo therapeutics and analysis of the TGF-beta system.

Purpose of the Study:

  • To investigate the therapeutic potential of short hairpin RNA (shRNA) targeting TGF-betaRII in liver injury.
  • To evaluate the efficacy of RNAi-mediated TGF-betaRII gene silencing in human and mouse models of liver damage.

Main Methods:

  • Utilized short hairpin RNA (shRNA) designed to target TGF-betaRII.
  • Investigated the effects of shRNA in human and mouse cell lines experiencing hepatocyte injury.
  • Employed mouse models to assess the impact of shRNA on liver injury and acute liver failure.

Main Results:

  • Demonstrated successful silencing of TGF-betaRII genes in both mouse and human cell lines using shRNA.
  • Showed that RNAi-mediated silencing of TGF-betaRII protected hepatocytes from acute injury by suppressing downstream signaling.
  • Confirmed that shRNA targeting TGF-betaRII provided protection against life-threatening acute liver failure in mice.

Conclusions:

  • TGF-betaRII silencing via RNAi is a viable strategy for gene-specific therapy in human disorders.
  • RNAi-mediated TGF-betaRII gene silencing can serve as an effective analytical tool for studying TGF-beta signaling pathways.
  • This approach holds significant promise for developing novel treatments for liver diseases and other TGF-beta-related conditions.

More Related Videos

Cell Type-specific Gene Expression Profiling in the Mouse Liver10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...